Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Siegel R.L. et al. Cancer statistics 2015. CA Cancer J Clin 2015;65:5.
  2. Soria F. et al. Epidemiology diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017;35:379.
  3. Margulis V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224.
  4. Shariat S.F. et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011;29:481.
  5. Roupret M. et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008;54:1226.
  6. Acher P. et al. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int 2010;106:300.
  7. Matin S.F. et al. Misclassification of Upper Tract Urothelial Carcinoma in Patients with Lynch Syndrome. JAMA Oncol 2018;4:1010.
  8. Therkildsen C. et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol 2018;12:1286.
  9. Colin P. et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009;104:1436.
  10. Crivelli J.J. et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65:742.
  11. Cosyns J.P. Aristolochic acid and “Chinese herbs nephropathy”: a review of the evidence to date. Drug Saf 2003;26:33.
  12. Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013;54:1.
  13. Rosenquist T.A. et al. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst) 2016;44:205.
  14. Jelakovic B. et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81:559.
  15. Chen C.H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012;109:8241.
  16. Nortier J.L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686.
  17. Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013;54:1.
  18. Babjuk M. et al. EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS). In: EAU guidelines, presented at the 34th EAU Annual Congress. Barcelona:EAU Guidelines Office, 2019.
  19. Siegel R.L. et al. Cancer statistics, 2017. CA Cancer J Clin 2017;66:7.
  20. Munoz J.J. et al. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000;164:1523.
  21. Cosentino M. et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol2013;31:141.
  22. Xylinas E. et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol2012;61:1069.
  23. Li W.M. et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010;57:963.
  24. Inman B.A., et al. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer 2009;115:2853.
  25. Cowan N.C. CT urography for hematuria. Nat Rev Urol 2012;9:218.
  26. Ito Y. et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol2011;185:1621.
  27. Raman J.D. et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 2011; 29:716.
  28. Reynolds J.P. et al. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathol 2014;122:459.
  29. Hurel S. et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol 2015;33:335.
  30. Verhoest G. et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol 2011;29:495.
  31. Takahashi N. et al. Gadolinium enhanced magnetic resonance urography forupper urinary tract malignancy. J Urol2010;183:1330.
  32. Walton T.J. et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 2011;108:406.
  33. Marchioni M. et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int 2017;120:313.
  34. Guo R.Q. et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int 2018;121:184.
  35. Bus M.T. et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol 2015;29:113.
  36. Brien J.C. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol2010;184:69.
  37. Abouassaly R. et al. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010;76:895.
  38. Kata S.G. et al. Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour. Photodiagnosis Photodyn Ther 2016;13:255.
  39. Matsumoto K. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2011;108:E304.
  40. Singla N. et al. A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol 2017;197:1208.
  41. Fajkovic H. et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol 2012;187:845.
  42. Roscigno M. et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60:776.
  43. Lughezzani G. et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology2010;75:118.
  44. Simsir A. et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol2011;43:1039.
  45. Rink M. et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol2013;63:1082.
  46. Sundi D. et al. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol 2012;30:266.
  47. Gadzinski A.J. et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol 2012;26:566.
  48. Lee J.N. et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol 2014;110:468.
  49. Waldert M. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010;105:812.
  50. Favaretto R.L. et al. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol 2017;35:113.
  51. Scarpini S. et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2012;30:182.
  52. Roupret M. et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005;65:1233.
  53. Krabbe L.M. et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol2017;198:1253.
  54. Seisen T. et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol2015;67:1122.
  55. Seisen T. et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Nonmuscle Invasive Bladder Cancer Guidelines Panel. Eur Urol2016;70:1052.
  56. Leow J.J. et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66:529.
  57. Cutress M.L. et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012;110:614.
  58. Cornu J.N. et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol2010;28:151.
  59. Jeldres C. et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010;183:1324.
  60. Colin P. et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012;110:1134.
  61. Lopez-Beltran A. et al. Tumours of the urinary system. In: World Health Organizationclassification of tumors: pathology and genetics of tumours of the urinary system and male genital organs. Eds.: Eble J.N. et al. Lyon: IARC Press, 2004.
  62. Irie A. et al. Intravesical instillation of bacille Calmette–Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 2002;59:53.
  63. Horiguchi H. et al. Impact of bacillus Calmette–Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol2018;35:41.
  64. Tomisaki I. et al. Efficacy and tolerability of bacillus Calmette–Guerin therapy as the first-line therapy for upper urinary tract carcinoma in situ. Cancer Invest 2018;36:152.
  65. Yossepowitch O. et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 2005;173:890.
  66. Ong A.M. et al. Trocar site recurrence after laparoscopic nephroureterectomy. J Urol 2003;170:1301.
  67. Ni S. et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012;61:1142.
  68. Ariane M.M. et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol2012;19:301.
  69. Simone G. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomized prospective study. Eur Urol 2009;56:520.
  70. Adibi M. et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 2012;19:1060.
  71. Clements M.B. et al. Robotic-assisted surgery for upper tract urothelial carcinoma: a comparative survival analysis. Ann Surg Oncol 2018;25:2550.
  72. Rodriguez J.F. et al. Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol2017;31:661.
  73. Aboumohamed A.A., et al. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015;194:1561.
  74. Moschini M. et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017;35:1541.
  75. Zareba P. et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer 2017;123:1741.
  76. Dominguez-Escrig J.L. et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus 2019:5:224.
  77. Giannarini G. et al. Antegrade perfusion with bacillus Calmette–Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 2011;60:955.
  78. Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998;16:1099.
  79. Matin S.F. et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116:3127.
  80. Liao R.S. et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol2018;200:68.
  81. Porten S. et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014;120:1794.
  82. KubotaY. et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 2017;8:101500.
  83. Moschini M. et al. Impact of primary tumor location on survival from the European Organization For The Research And Treatment Of Cancer Advanced Urothelial Cancer Studies. J Urol 2018;199:1149.
  84. Balar A.V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483.
  85. Balar A.V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67.
  86. Heers H. et al. Vinflunine in the treatment of upper tract urothelial carcinoma –subgroup analysis of an observational study. Anticancer Res 2017;37:6437.
  87. Rosenberg J.E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 2016;387:1909.
  88. Powles T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018;391:748.
  89. Goldberg H. et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget 2018;9:18797.
  90. Necchi A. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2018;121:252.
  91. Fujita K. et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol2017;17:110.
  92. Birtle A.J. et al. Results of POUT: A phase III randomized trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 2018;36:407.
  93. Faltas B.M. et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol2018;36:9.e11.
  94. Ploussard G. et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol2015;67:803.
  95. Shigeta K. et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol 2017;198:1278.
  96. Sudakoff, G.S., et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol, 2008. 179: 862.
  97. Wang, L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524.
  98. Wang, L.J., et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol, 2010. 183: 48.
  99. Jinzaki, M., et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol, 2011. 196: 1102.
  100. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Kamat AM1, Bellmunt J2, Galsky MD J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0.
  101. Czito, B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172(4 Pt 1):1271.https://www.ncbi.nlm.nih.gov/pubmed/15371822
  102. Rev Urol. 2006 Spring; 8(2): 61–70.Treatment of Upper Tract Urothelial Carcinoma: A Review of Surgical and Adjuvant Therapy Kalyan C Latchamsetty, MD and Christopher R Porter, MDCancer Med. 2018 Dec; 7(12): 6112–6123. Validation of the preoperative controlling nutritional status score as an independent predictor in a large Chinese cohort of patients with upper tract urothelial carcinoma Hang Xu, 1 Ping Tan, 1 Xi Jin,
  103. Gopalakrishna A , Longo TA , Fantony JJ , et al . Lifestyle factors and health-related quality of life in bladder Cancer survivors: a systematic review. J Cancer Surviv 2016;10:874–82.doi:10.1007/s11764-016-0533-8
  104. Maloney, I., Parker, D. C., Cookson, M. S., & Patel, S. (2017). Bladder Cancer Recovery Pathways: A Systematic Review. Bladder cancer (Amsterdam, Netherlands), 3(4), 269–281.
  105. Silverdale N, Wherry M, Roodhouse A. Massage and reflexology for post-operative cancer cystectomy patients: Evaluation of a pilot service. Complement Ther Clin Pract. 2019 Feb;34:109-112
  106. 49 Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017). PM R. 2017 Sep;9(9S2):S347-S384
  107. Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH1, Torres MA, Dunlop BW, Rakofsky JJ, Rapaport MH. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018 Feb 1;124(3):546-554
  108. Streckmann F, Zopf EM, Lehmann HC, et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289-1304
  109. Kleckner IR, Kamen C, Gewandter JS, et al: Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019-1028
  110. Muzi JL, Look RM., Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C, Garrett K, Johnson N. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9019-9019
  111. 54 Rick, O., von Hehn, U., Mikus, E., Dertinger, H., & Geiger, G. (2016). Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics, 38(2), 85-94
  112. Kılınç M, Livanelioğlu A, Yıldırım SA, Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014 May;46(5):454-60. doi: 10.2340/16501977-1271
  113. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One. 2014 Sep 8;9(9):e107418
  114. Ross M, Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs. 2017 Apr 1;21(2):226-233. doi: 10.1188/17.CJON.226-233
  115. Visser, Wilhelmina S et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Annals of coloproctology vol. 30,3 (2014): 109-14
  116. Avci, P., Gupta, G. K.,Clark, J., Wikonkal, N., & Hamblin, M. R. (2013). Low-level laser (light) therapy (LLLT) fortreatment of hair loss. Lasers in surgery and medicine, 46(2), 144-51
  117. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2019 Update [Электронныйисточник]// European Association of Urology [сайт]. URL: https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/ (датаобращения: 20.11.2019)
  118. Redrow, G.P., et al. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol, 2017. 197: 287.
  119. Giannarini, G., et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscleinvasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol, 2011. 60: 955
  120. Pollard ME, Levinson AW, Shapiro EY, et al: Comparison of 3 Upper Tract
  121. Anticarcinogenic Agent Delivery Techniques in an Ex Vivo Porcine Model. Urology 2013;82: 1451. e1–1451. e6.
  122. Roupret M, Babjuk M, Comperat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018;73:111-122. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28867446.
  123. Mandalapu RS, Remzi M, de Reijke TM, et al. Update of the ICUD- SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol 2017;35:355-365. Available at:https://www.ncbi.nlm.nih.gov/pubmed/27233780.
  124. O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60:703-710. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21684068.
  125. Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013;31:1422-1427. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23460707.
  126. Miyamoto K, Ito A, Wakabayashi M, et al. A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III). Jpn J Clin Oncol 2018;48:94-97. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29136187.
  127. Kim DK, Lee JY, Kim JW, et al. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2019;135:59-65. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30819447.
  128. Audenet, F., et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol, 2013. 31: 407.
  129. Kaag, M.G., et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol, 2010. 58: 581. https://www.ncbi.nlm.nih.gov/pubmed/20619530
  130. Lane, B.R., et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer, 2010. 116: 2967. https://www.ncbi.nlm.nih.gov/pubmed/20564402
  131. Goldberg, H., et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget, 2018. 9: 18797. https://www.ncbi.nlm.nih.gov/pubmed/29721162
  132. Necchi, A., et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int, 2018. 121: 252. https://www.ncbi.nlm.nih.gov/pubmed/28940605
  133. Fujita, K., et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol, 2017. 17: 110. https://www.ncbi.nlm.nih.gov/pubmed/29195499
  134. Seisen, T., et al. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol, 2017. 35: 852. https://www.ncbi.nlm.nih.gov/pubmed/28045620].
  135. Birtle, A.J., et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol, 2018. 36: 407. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.407
  136. Нahn, A.W., et al. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res, 2016. 36: 4051.https://www.ncbi.nlm.nih.gov/pubmed/27466512
  137. Huang, Y.C., et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep, 2016. 6: 38175. https://www.ncbi.nlm.nih.gov/pubmed/27910890
  138. .Czito, B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172(4 Pt 1):1271. https://www.ncbi.nlm.nih.gov/pubmed/15371822
  139. Shigeta, K., et al. The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. J Urol, 2017. 198: 1278.https://www.ncbi.nlm.nih.gov/pubmed/28634017
  140. Bellmunt J. et al. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012. 39: 598.
  141. Sternberg C.N. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001. 19: 2638.
  142. Galsky M.D. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 2011. 29: 2432.
  143. De Santis M. et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol 2009. 27: 5634.
  144. Sudakoff, G.S., et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol, 2008. 179:862.https://www.ncbi.nlm.nih.gov/pubmed/18221955
  145. Wang, L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524.https://www.ncbi.nlm.nih.gov/pubmed/19100576
  146. Wang, L.J., et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol, 2010. 183: 48. https://www.ncbi.nlm.nih.gov/pubmed/19913253
  147. Jinzaki, M., et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol, 2011. 196: 1102. https://www.ncbi.nlm.nih.gov/pubmed/21512076
  148. Rosenthal DL, et al. The Paris System for Reporting Urinary Cytology. 2016, Switzerland 2016.
  149. Chen, A.A., et al. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J Endourol, 2008. 22: 1371. https://www.ncbi.nlm.nih.gov/pubmed/18578665
  150. Johannes, J.R., et al. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol, 2010. 184: 879. https://www.ncbi.nlm.nih.gov/pubmed/20643443
  151. Cowan, N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363.https://www.ncbi.nlm.nih.gov/pubmed/17428251
  152. Lee, K.S., et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol, 2010. 65: 185. https://www.ncbi.nlm.nih.gov/pubmed/20152273
  153. Cutress, M.L., et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int, 2012. 110: 614. https://www.ncbi.nlm.nih.gov/pubmed/22471401
  154. Roupret, M., et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol, 2007. 51: 709. https://www.ncbi.nlm.nih.gov/pubmed/16911852
  155. Song, Y. S., Cho, J. S., Cho, K. S., Doo, S. H., Chung, B. H., Kim, S. J., … Hong, S. J. (2010). Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract. Urologia Internationalis, 85(1), 47–51. doi:10.1159/000296294
  156. Bellmunt, J., de Wit, R., Albanell, J., & Baselga, J. (2001). A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. European Journal of Cancer, 37(17), 2212–2215. doi:10.1016/s0959-8049(01)00295-7
  157. https://rosoncoweb.ru/standarts/RUSSCO/2015/28.pdf
  158. Bellmunt J, de Wit R, Vaughn DJ, et al. on behalf of the keynote-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015–26. doi: 10.1056/NEJMoa1613683.
  159. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22. doi: 10.1016/S1470-2045(17)30065-7.
  160. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20. doi: 10.1016/S0140-6736(16)00561-4.
  161. Приказ от 24 марта 2016 г. № 179н министерства здравоохранения Российской Федерации О Правилах проведения патолого-анатомических исследованийhttp://pravo.gov.ru/proxy/ips/?doc_itself=&backlink=1&nd=102396069&page=1&rdk=0#I0
  162. Приказ от 10 мая 2017 г. N 203нминистерства здравоохранения Российской ФедерацииОБ УТВЕРЖДЕНИИ КРИТЕРИЕВ ОЦЕНКИ КАЧЕСТВА МЕДИЦИНСКОЙ ПОМОЩИ
  163. Dean F Bajorin et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021 Jun 3; 384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
  164. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma.
  165. Bamias A, Aravantinos G, Deliveliotis C, et al: Docetaxel and cisplatin with granulocyte colonystimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:220-228, 2004
  166. Choueiri T. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.J Clin Oncol. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. Epub 2014 May 12.
  167. Culine S. et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006. 94: 1395.
  168. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial cancer. N Engl J Med. 2020;383:1218-1230.
  169. Galsky et al. Atezolizumab With or Without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial Lancet 2020 May 16; 395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0.
  170. Yucai Wang et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0393.
  171. T. Powles, et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 38: 2020 (suppl; abstr LBA1).
  172. Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H, Ito F, Tanabe K. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol. 2010 Oct;17(10):848-54. doi: 10.1111/j.1442-2042.2010.02610.x. Epub 2010 Aug 31. PMID: 20812922.
  173. Foerster B, D'Andrea D, Abufaraj M, Broenimann S, Karakiewicz PI, Rouprêt M, Gontero P, Lerner SP, Shariat SF, Soria F. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol. 2019 Jul;37(7):430-436.
  174. Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int. 2013;91(3):291-6.
  175. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 2004 Oct;172(4 Pt 1):1271-5.
  176. Iwata T, Kimura S, Abufaraj M, Janisch F, Karakiewicz PI, Seebacher V, Rouprêt M, Nasu Y, Shariat SF. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol. 2019 Oct;37(10):659-671.
  177. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102-2114.
  178. H. von der Maase , S.W. Hansen , J.T. Roberts , L. Dogliotti , T. Oliver , M.J. Moore. Show MoreGemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology 18, no. 17 (September 17, 2000) 3068-3077.
  179. H. von der Maase , S.W. Hansen , J.T. Roberts , L. Dogliotti , T. Oliver , M.J. Moore...Show MoreGemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. JournalofClinicalOncology 18, no. 17 (September 17, 2000) 3068-3077.
  180. Пембролизумаб. Инструкция к лекарственному препарату ЛП-003972,2021.
  181. Атезолизумаб. Инструкция к лекарственному препарату.
    ЛП-004652-030620. Изм. №1 к ЛП-004652-030620
  182. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N SOJ Clin Oncol. 1997;15(12):3441
  183. Albers, P., et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie, 2002. 25: 27.
  184. Sternberg CN, Loriot Y, James N, . Primary results from SAUL, a multinational ingle-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol2019;76:73–81. Sharma P., Callahan M.K., Bono P., Kim J., Spiliopoulou P., Calvo E., Pillai R.N., Ott P.A., de Braud F., Morse M., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (checkmate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17:1590–1598.
  185. Lindner A.K., Schachtner G., Tulchiner G. et al. Lynch syndrome: its impact on urothelial carcinoma. Int J Mol Sci. 2021;22(2):531.
  186. Mikhaylenko D.S., Tanas A.S., Zaletaev D.V., Nemtsova M.V. Application areas of traditional molecular genetic methods and NGS in relation to hereditary urological cancer diagnosis. J Oncol. 2020;7363102.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*